Publication date: Aug 01, 2024
In April 2020, the UK Government implemented NHS Test and Trace to provide SARS-CoV-2 quantitative reverse transcription polymerase chain reaction (qRT-PCR) testing for the public, with nose-and-throat swabbing for samples performed by trained staff. Self-swabbing (SS) would allow rapid scale-up of testing capacity and access. Six studies were undertaken to determine whether SS was as effective for detecting SARS-CoV-2 as swabbing performed by trained staff. Six prospective studies were conducted between April-October 2020, using six swab/media combinations. Differences between assisted swabbing (AS) and SS were evaluated for concordance, positivity, sensitivity, cycle threshold (Ct) values and void rates. Statistical analysis was performed using 95% confidence intervals (CIs), paired t-tests and model-based methods. Overall, 3,253 individuals were recruited (median age 37 years, 49% female), with 2,933 having valid paired qRT-PCR results. Pooled concordance rate was 98% (95% CI: 96%, 99%). Positivity rate differences for SS (8. 1%) and AS (8. 4%) and differences in pooled sensitivities between SS (86%; 95% CI: 78%, 92%) and AS (91%; 95% CI: 78%, 96%) were nonsignificant. Both types of swabbing led to pooled void rates below 2% and strongly correlated Ct values. Age, sex and previous swabbing experience did not have a significant impact on concordance or sensitivity. The UK adopted a policy to promote self-testing for SARS-CoV-2 based on data demonstrating equivalence of SS versus AS. Positive outcomes with SS are likely generalisable to testing for other respiratory pathogens, and we consider self-sampling and self-testing essential for future pandemic preparedness.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | VO | nose |
drug | DRUGBANK | Etoperidone |
disease | VO | effective |
disease | VO | age |
disease | MESH | Infectious Diseases |
disease | MESH | Infections |
disease | MESH | COVID 19 |
disease | MESH | severe acute respiratory syndrome |
drug | DRUGBANK | Ademetionine |
drug | DRUGBANK | Serine |
disease | VO | time |
disease | VO | device |
drug | DRUGBANK | Coenzyme M |
disease | VO | manufacturer |
disease | IDO | site |
disease | VO | volume |
disease | VO | data set |
drug | DRUGBANK | Crofelemer |
disease | VO | Iss |
drug | DRUGBANK | Indoleacetic acid |
disease | VO | population |
drug | DRUGBANK | Ilex paraguariensis leaf |
disease | MESH | syndrome |
disease | VO | USA |
disease | IDO | process |
disease | VO | viable |
disease | MESH | uncertainty |
drug | DRUGBANK | Trestolone |
disease | IDO | infectivity |
drug | DRUGBANK | Cysteamine |
drug | DRUGBANK | Mexiletine |
disease | VO | company |
drug | DRUGBANK | (S)-Des-Me-Ampa |
disease | MESH | influenza |
disease | IDO | intervention |
disease | IDO | facility |
disease | VO | Severe acute respiratory syndrome coronavirus 2 |